



**HAL**  
open science

## Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area

Caroline Gay, Richard Delarue, Noël Milpied, Lucie Oberic, Bertrand Coiffier, Sami Boussetta, Corinne Haioun, Hervé Tilly, Gilles Salles, Thierry Lamy, et al.

### ► To cite this version:

Caroline Gay, Richard Delarue, Noël Milpied, Lucie Oberic, Bertrand Coiffier, et al.. Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. *Blood*, 2017, 129 (20), pp.2811-2813. 10.1182/blood-2017-02-766147 . hal-01558813

**HAL Id: hal-01558813**

**<https://univ-rennes.hal.science/hal-01558813>**

Submitted on 16 May 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated Body Surface Area

Caroline Gay<sup>1</sup>, Richard Delarue<sup>2</sup>, Noel Milpied<sup>3</sup>, Lucie Oberic<sup>4</sup>, Bertrand Coiffier<sup>5</sup>, Sami Boussetta<sup>6</sup>, Corinne Haioun<sup>7</sup>, Hervé Tilly<sup>8</sup>, Gilles Salles<sup>5</sup>, Thierry Lamy<sup>9</sup>, Marie-Antoinette Lester<sup>1,\*</sup>, Roch Houot<sup>9,\*</sup>

(\*) *equal contribution*

<sup>1</sup> CHU Rennes, Service de Pharmacie, F-35033 Rennes, France

<sup>2</sup> AP-HP, Hôpital universitaire Necker Enfants malades, Service d'hématologie adultes, 75015 Paris, France

<sup>3</sup> CHU Bordeaux, Service d'Hématologie et thérapie cellulaire and University of Bordeaux, Bordeaux, France

<sup>4</sup> Institut Universitaire du Cancer-Oncopole de Toulouse, Département d'Hématologie, Toulouse, France

<sup>5</sup> Hospices Civils de Lyon, Université Claude Bernard, Pierre-Bénite, France

<sup>6</sup> Lymphoma Academic Research Organisation, Centre Hospitalier Lyon-Sud, Lyon, France

<sup>7</sup> Hospital Henri Mondor, Lymphoid Malignancies Unit, Créteil, France

<sup>8</sup> Centre Henri Becquerel, UMR918, Université de Rouen, Rouen, France

<sup>9</sup> CHU Rennes, Service Hématologie Clinique, F-35033 Rennes, France

## Corresponding author :

Prof. Roch Houot  
Service d'Hématologie Clinique  
Hôpital Pontchaillou - CHU de Rennes  
2 rue Henri Le Guilloux  
35033 Rennes Cedex 9  
France  
Tel: +33 (0)2 99 28 42 26  
Fax: +33 (0)2 99 28 41 61  
Email : roch.houot@chu-rennes.fr

## **Letter to the editor**

In 2012, the American Society of Clinical Oncology (ASCO) published guidelines regarding the dosing of chemotherapy for obese patients with cancer<sup>1</sup>. In these patients, empiric dose reductions are often performed – usually by capping body surface area (BSA) at 2m<sup>2</sup> – because of concerns regarding toxicity. However, there is no evidence that administering a full dose of chemotherapy in obese patients with solid cancer is associated with an increased toxicity<sup>1</sup>. Additionally, the ASCO guidelines highlight the negative impact on prognosis of reduced doses of chemotherapy in obese patients with solid tumors and thus recommend the use of full weight-based doses of cytotoxic chemotherapy, particularly in curable cancers<sup>1</sup>. However, the impact of chemotherapy dosing has not been evaluated in non Hodgkin lymphoma (NHL) patients with elevated BSA.

In this study, we aimed to evaluate the impact of doxorubicin dose capping in patients with diffuse large B cell lymphoma (DLBCL). DLBCL is a curable disease in which relative dose intensity has been described to be associated with treatment efficacy<sup>2</sup>. However, clinicians may be concerned with the toxicity of high doses of anthracyclins in patients with elevated BSA.

To address this question, we analysed all DLBCL patients treated in first line in one of the following prospective LYSA, GELA and/or GOELAMS trials: LNH98-5, LNH-75, LNH03-2B, and LNH03-6B<sup>3;4;5;6</sup> (Supplementary Figure 1). All patients received (R-)CHOP or (R-)CHOP-like (mostly (R-)ACVBP) regimen. A theoretical BSA was calculated with Mosteller's formula for each patient according to their weight and height at inclusion. According to the dose planned in the protocol (theoretical dose) and the dose that was actually administered (observed dose), we could determine if the dose had been capped or not. Cut-off value for BSA was 2.1m<sup>2</sup>. Patients with a BSA of more than 2.1m<sup>2</sup> and doxorubicin dose capped at a BSA of 2m<sup>2</sup>, received less than 95% of the theoretical dose. Our cohort was divided into three groups: BSA<2.1m<sup>2</sup> (theoretical BSA and observed BSA<2.1m<sup>2</sup>), capped BSA≥2.1m<sup>2</sup> (theoretical BSA≥2.1m<sup>2</sup> and observed BSA<2.1m<sup>2</sup>) and uncapped BSA≥2.1m<sup>2</sup> (theoretical BSA and observed BSA≥2.1m<sup>2</sup>). Flow chart for patient selection is presented in Supplementary Figure 1.

A total of 1,384 patients were included in the analysis: 89% (N=1232) of the patients had a BSA<2.1m<sup>2</sup> (BSA<2.1m<sup>2</sup> group), 8.6% (N=119) had a BSA≥2.1m<sup>2</sup> and received a capped dose of doxorubicin (capped BSA≥2.1m<sup>2</sup> group) and 2.4% (N=33) had a BSA≥2.1m<sup>2</sup> and received a full weight dose of doxorubicin (uncapped BSA≥2.1m<sup>2</sup> group). Compared to patients with a BSA≥2.1m<sup>2</sup>, the patients with a BSA<2.1m<sup>2</sup> were older (74% of the patients were more than 60 years old *versus* 55.5% of patients in the capped BSA≥2.1m<sup>2</sup> group and 51.5% of patients in the uncapped BSA≥2.1m<sup>2</sup> group, p<0.001), had a lower BMI (58.8% had a BMI<25kg/m<sup>2</sup> *versus* 3.4% and 9.1%, respectively, p<0.001), were predominantly females (49.3% *versus* 10.1% and 6.1%, p<0.001), had a higher aalPI score (47% had an aalPI score>1 *versus* 37.8% and 30.3%, p<0.001) and had more B symptoms (36.2% *versus* 20.2% and 18.2%, p<0.001) (Supplementary Table 1). Groups were comparable for the following factors: Ann Arbor stage, number of extra nodal lesions and treatment regimens (R-CHOP, CHOP and R-ACVBP).

The rate of treatment-related death was 3.9% in the BSA<2.1m<sup>2</sup> group, 6.7% in the capped BSA≥2.1m<sup>2</sup> group and 6.1% in the uncapped BSA≥2.1m<sup>2</sup> group. These differences were not statistically significant (p=0.293) (Table 1).

PFS and OS for the three groups are shown in Figure 1. Median PFS was 78.7, 75.9 and 57.9 months for patients with BSA<2.1m<sup>2</sup>, capped BSA≥2.1m<sup>2</sup> and uncapped BSA≥2.1m<sup>2</sup>, respectively. Median OS was 106.5, 113.1 and 93.1 months, respectively. There was no statistical difference between the groups for PFS nor OS (p=0.481 and 0.864,

respectively)(Table 1). These results remained unchanged after adjusting for sex, aalPI score and BMI (Supplementary Table 2).

Our study did not show any impact of doxorubicin dose capping at  $2\text{m}^2$  on PFS nor OS in DLBCL patients with elevated BSA. Similar results were reported by Kempf *et al* in AML patients with an elevated BSA, except for the subgroup of obese patients with a favourable cytogenetic risk<sup>7</sup>. Changes in the pharmacokinetics of doxorubicin in patients with elevated BSA may have neutralized the impact of dose capping on the outcome. Indeed, doxorubicin clearance is reduced in obese patients thereby increases doxorubicin exposure<sup>8,9</sup>. In NHL patients, some retrospective studies have found that the outcome was better<sup>10,11</sup> or similar<sup>12</sup> in overweight and obese patients receiving full weight chemotherapy dosing compared to patients with normal BMI. Such difference was not found in the current study.

The treatment-related mortality did not differ between the three groups although high BMI and cumulative dose of anthracycline have been associated with higher risk of anthracycline cardiotoxicity<sup>13</sup>. In our study, the influence of confounding factors such as age, sex, performance status, and comorbidities could not be excluded. Ganti *et al* reported a lower incidence of treatment-related mortality in obese NHL patients, and a trend in overweight patients<sup>14</sup>. Other studies reported similar rates of hematologic and non-hematologic toxicities in full-dosed overweight and obese patients compared with normal weight patients<sup>9,10,12</sup>.



Interpretation of these results requires caution because of some limitations. First, this is an unplanned retrospective analysis. Second, the sample size of the patients with an elevated BSA and an uncapped dose of doxorubicin is small and may have underpowered the capacity to detect any statistical difference in survival or treatment-related mortality. Indeed, the power estimated for the PFS analysis with this sample size was 60%. Finally, the groups were not comparable for several prognostic factors that may influence prognosis and toxicity.

In conclusion, our study did not demonstrate inferior efficacy when doxorubicin dose was capped at  $2\text{m}^2$  in DLBCL patients with elevated BSA. On the other hand, uncapped dosing of doxorubicin did not seem to increase the incidence of treatment-related mortality. Therefore, these two options seem acceptable in DLBCL patients with elevated BSA.

**Contribution:** R.H. and M-A. L. designed the research, analyzed data and wrote the paper. C.G. and S.B. analyzed data and wrote the paper. R.D., N.M., L.O., B.C., C.H., H.T., G.S., and T.L. provided the data and wrote the paper. All authors reviewed and approved the final draft.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests

Figure 1. Progression-free survival (A) and overall survival (B) according to BSA and doxorubicin dose adaptation in patients with DLBCL (Log-rank  $p=0.481$  and  $p=0.864$ , respectively).



**Table 1. Treatment-related mortality, progression free survival and overall survival according to BSA and doxorubicin dose adaptation in patients with DLBCL.**

	<b>BSA&lt;2.1m<sup>2</sup></b>	<b>BSA capped≥2.1m<sup>2</sup></b>	<b>BSA uncapped≥2.1m<sup>2</sup></b>	<b>p value</b>
Number (%)	1.232 (89%)	119 (8.6%)	33 (2.4%)	
Treatment-related mortality	3.9%	6.7%	6.1%	0.293 <sup>1</sup>
Median PFS (95%CI)	78.7 [64.6 ; 91.4]	75.9 [49.7 ; NA]	57.9 [13.5 ; NA]	0.481 <sup>2</sup>
Median OS (95%CI)	106.5 [93.1 ; 117.9]	113.1 [75.9 ; NA]	93.1 [32.6 ; NA]	0.864 <sup>2</sup>

<sup>1</sup>  $\chi^2$  test was performed.

<sup>2</sup> Log-rank test was performed. Test was two sided.  
Significance level is p<0.05

## References

1. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2012;30(13):1553–1561.
2. Gutiérrez A, Bento L, Bautista-Gili AM, et al. Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. *PLoS ONE.* 2015;10(4):.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N. Engl. J. Med.* 2002;346(4):235–242.
4. Le Gouill S, Milpied NJ, Lamy T, et al. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. *ASCO Meet. Abstr.* 2011;29(15\_suppl):8003.
5. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet Lond. Engl.* 2011;378(9806):1858–1867.
6. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. *Lancet Oncol.* 2013;14(6):525–533.
7. Kempf E, Hirsch P, Labopin M, et al. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. *Leuk. Res.* 2014;38(12):1425–1429.
8. Sparreboom A, Wolff AC, Mathijssen RHJ, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2007;25(30):4707–4713.
9. Hoffmann M, Bergner R, Stützle M, Uppenkamp MJ, Foerster R. Pharmacokinetics of Doxorubicin In Normal Weight and Obese Lymphoma Patients. *Blood.* 2010;116(21):4935–4935.
10. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. *Leuk. Lymphoma.* 2010;51(9):1649–1657.
11. Weiss L, Melchardt T, Habringer S, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO.* 2014;25(1):171–176.
12. Chan H, Jackson S, McLay J, et al. Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. *Leuk. Lymphoma.* 2016;1–9.
13. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. *Am. J. Cardiol.* 2013;112(12):1980–1984.
14. Ganti A, Liu W, Luo S, et al. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. *Br. J. Haematol.* 2014;167(5):699–702.